NCT06138795 - A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

August 24, 2025

Study Completion Date

August 24, 2025

Conditions

Healthy Participants

Interventions

DRUG

AZD2389

Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

DRUG

Placebo

Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Trial Locations (1)

Research Site, Glendale